Mrs Allison Steigler

Statistician

School of Medicine and Public Health

Career Summary

Biography

Research Expertise

Since 2003 I have the trial coordinator of the TROG 96.01 prostate cancer trial.


Qualifications

  • Bachelor of Mathematics, University of Newcastle

Keywords

  • clinical trials
  • prostate cancer

Fields of Research

CodeDescriptionPercentage
029999Physical Sciences not elsewhere classified50
110399Clinical Sciences not elsewhere classified25
111299Oncology and Carcinogenesis not elsewhere classified25
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (32 outputs)

YearCitationAltmetricsLink
2015Denham JW, Steigler A, Joseph D, Lamb DS, Spry NA, Duchesne G, et al., 'Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial.', Radiother Oncol, (2015)
DOI10.1016/j.radonc.2015.05.016Author URL
Co-authorsChristopher Oldmeadow, Liz Holliday, John Attia
2014Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, et al., 'Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer', BJU International, 114 344-353 (2014) [C1]

Objective To study the influence of adjuvant androgen suppression and bisphosphonates on incident vertebral and non-spinal fracture rates and bone mineral density (BMD) in men wit... [more]

Objective To study the influence of adjuvant androgen suppression and bisphosphonates on incident vertebral and non-spinal fracture rates and bone mineral density (BMD) in men with locally advanced prostate cancer. Patients and Methods Between 2003 and 2007, 1071 men with locally advanced prostate cancer were randomly allocated, using a 2 × 2 trial design, to 6 months i.m. leuprorelin (androgen suppression [AS]) before radiotherapy alone ± 12 months additional leuprorelin ± 18 months zoledronic acid (ZdA), commencing at randomization. The main endpoint was incident thoraco-lumbar vertebral fractures, which were assessed radiographically at randomization and at 3 years, then reassessed by centralized review. Subsidiary endpoints included incident non-spinal fractures, which were documented throughout follow-up, and BMD, which was measured in 222 subjects at baseline, 2 years and 4 years. Results Incident vertebral fractures at 3 years were observed in 132 subjects. Their occurrence was not increased by 18 months' AS, nor reduced by ZdA. Incident non-spinal fractures occurred in 72 subjects and were significantly related to AS duration but not to ZdA. Osteopenia and osteoporosis prevalence rates at baseline were 23.4 and 1.4%, respectively, at the hip. Treatment for 6 and 18 months with AS caused significant reductions in hip BMD at 2 and 4 years (P < 0.01) and ZdA prevented these losses at both time points. Conclusion In an AS-naïve population, 18 months of ZdA treatment prevented the sustained BMD losses caused by 18 months of AS treatment; however, the study power was insufficient to show that AS duration or ZdA influenced vertebral fracture rates. © 2013 The Authors. BJU International © 2013 BJU International.

DOI10.1111/bju.12497
CitationsScopus - 2Web of Science - 6
Co-authorsCatherine Deste, Pablo Moscato
2014Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, et al., 'Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer', BJU International, 114 344-353 (2014) [C1]

Objective To study the influence of adjuvant androgen suppression and bisphosphonates on incident vertebral and non-spinal fracture rates and bone mineral density (BMD) in men wit... [more]

Objective To study the influence of adjuvant androgen suppression and bisphosphonates on incident vertebral and non-spinal fracture rates and bone mineral density (BMD) in men with locally advanced prostate cancer. Patients and Methods Between 2003 and 2007, 1071 men with locally advanced prostate cancer were randomly allocated, using a 2 × 2 trial design, to 6 months i.m. leuprorelin (androgen suppression [AS]) before radiotherapy alone ± 12 months additional leuprorelin ± 18 months zoledronic acid (ZdA), commencing at randomization. The main endpoint was incident thoraco-lumbar vertebral fractures, which were assessed radiographically at randomization and at 3 years, then reassessed by centralized review. Subsidiary endpoints included incident non-spinal fractures, which were documented throughout follow-up, and BMD, which was measured in 222 subjects at baseline, 2 years and 4 years. Results Incident vertebral fractures at 3 years were observed in 132 subjects. Their occurrence was not increased by 18 months' AS, nor reduced by ZdA. Incident non-spinal fractures occurred in 72 subjects and were significantly related to AS duration but not to ZdA. Osteopenia and osteoporosis prevalence rates at baseline were 23.4 and 1.4%, respectively, at the hip. Treatment for 6 and 18 months with AS caused significant reductions in hip BMD at 2 and 4 years (P < 0.01) and ZdA prevented these losses at both time points. Conclusion In an AS-naïve population, 18 months of ZdA treatment prevented the sustained BMD losses caused by 18 months of AS treatment; however, the study power was insufficient to show that AS duration or ZdA influenced vertebral fracture rates. © 2013 The Authors. BJU International © 2013 BJU International.

DOI10.1111/bju.12497
CitationsScopus - 2
Co-authorsCatherine Deste, Pablo Moscato
2014Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, et al., 'Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial', LANCET ONCOLOGY, 15 1076-1089 (2014) [C1]
DOI10.1016/S1470-2045(14)70328-6Author URL
CitationsScopus - 2Web of Science - 2
Co-authorsJohn Attia, Christopher Oldmeadow
2014Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, et al., 'Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.', BJU Int, 114 344-353 (2014) [C1]
DOI10.1111/bju.12497Author URL
CitationsWeb of Science - 6
Co-authorsPablo Moscato, Catherine Deste
2013Denham JW, Steigler A, Tai K, Joseph D, Matthews J, Atkinson C, et al., 'Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer', Radiotherapy and Oncology, 107 123-128 (2013) [C1]
DOI10.1016/j.radonc.2013.03.025Author URL
CitationsScopus - 2Web of Science - 1
2013Denham JW, Steigler A, 'Picking the Optimal Duration of Hormonal Therapy in Men With High-Risk and Locally Advanced Prostate Cancer Treated With Radiotherapy', Seminars in Radiation Oncology, 23 206-214 (2013) [C1]
DOI10.1016/j.semradonc.2013.01.008Author URL
2012Wilcox C, Kautto AJ, Steigler A, Denham J, 'Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term', Oncology: International Journal of Cancer Research and Treatment, 82 56-58 (2012) [C1]
CitationsScopus - 6Web of Science - 7
2012D'Amico AV, Chen M-H, De Castro M, De Castro M, Lamb DS, Steigler A, et al., 'Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: An analysis of two randomised trials', Lancet Oncology, 13 189-195 (2012) [C1]
CitationsScopus - 16Web of Science - 14
2012Steigler A, Denham J, Lamb DS, Spry NA, Joseph D, Matthews J, et al., 'Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: Data from the TROG 96.01 trial', Prostate Cancer, 2012 1-11 (2012) [C1]
2011Ebert MA, Lamb DS, Joseph DJ, Steigler A, Denham J, 'A methodology for the analysis of PSA response signatures', Radiotherapy and Oncology, 98 198-202 (2011) [C1]
DOI10.1016/j.radonc.2010.11.013
CitationsScopus - 1
2011Denham J, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry NA, et al., 'Another form of subgroup to beware', Radiotherapy and Oncology, 101 525-526 (2011) [C3]
DOI10.1016/j.radonc.2011.08.032
CitationsScopus - 1Web of Science - 1
Co-authorsCatherine Deste
2011Lamb DS, Denham J, Joseph D, Matthews J, Atkinson C, Spry NA, et al., 'A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: Analysis of data from the TROG 96.01 randomized trial', International Journal of Radiation Oncology Biology Physics, 79 385-391 (2011) [C1]
DOI10.1016/j.ijrobp.2009.10.071
CitationsScopus - 15Web of Science - 13
Co-authorsCatherine Deste
2011D'Amico AV, Chen MH, Crook J, Armstrong JG, Malone S, Steigler A, et al., 'Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer', Journal of Clinical Oncology, 29 4682-4687 (2011) [C1]
DOI10.1200/jco.2011.37.0726
CitationsScopus - 5Web of Science - 5
2011Denham J, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, et al., 'Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial', The Lancet Oncology, 12 451-459 (2011) [C1]
DOI10.1016/s1470-2045(11)70063-8
CitationsScopus - 113Web of Science - 101
Co-authorsCatherine Deste
2010Kumar M, Denham J, Steigler A, 'Value of combined androgen blockade in the neoadjuvant treatment of localized prostate cancer: The jury must remain out', Journal of Clinical Oncology, 28 E445-E446 (2010) [C3]
DOI10.1200/JCO.2010.29.4868
CitationsScopus - 1Web of Science - 1
2009Denham J, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, et al., 'Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?', Cancer, 115 4477-4487 (2009) [C1]
DOI10.1002/cncr.24484
CitationsScopus - 18Web of Science - 17
Co-authorsCatherine Deste
2009Denham J, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry NA, et al., 'PSA response signatures: A powerful new prognostic indicator after radiation for prostate cancer?', Radiotherapy and Oncology, 90 382-388 (2009) [C1]
DOI10.1016/j.radonc.2008.10.004
CitationsScopus - 11Web of Science - 11
Co-authorsCatherine Deste
2009Capp A, Inostroza-Ponta M, Bill D, Moscato PA, Lai C, Christie D, et al., 'Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial', Radiotherapy and Oncology, 90 400-407 (2009) [C1]
DOI10.1016/j.radonc.2008.09.019
CitationsScopus - 40Web of Science - 35
Co-authorsPablo Moscato
2009Denham J, Kumar M, Gleeson PS, Lamb DS, Joseph D, Atkinson C, et al., 'Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer', International Journal of Radiation Oncology Biology Physics, 74 404-411 (2009) [C1]
DOI10.1016/j.ijrobp.2008.08.047
CitationsScopus - 7Web of Science - 6
Co-authorsCatherine Deste, Peter Greer
2009Denham J, Steigler A, Kumar M, Lamb DS, Joseph D, Spry NA, et al., 'Measuring time to biochemical failure in the Trog 96.01 trial: When should the clock start ticking?', International Journal of Radiation Oncology Biology Physics, 75 1008-1012 (2009) [C1]
DOI10.1016/j.ijrobp.2008.12.085
CitationsScopus - 4Web of Science - 3
Co-authorsCatherine Deste, Peter Greer
2008Denham J, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, et al., 'Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial', Lancet Oncology, 9 1058-1068 (2008) [C1]
DOI10.1016/s1470-2045(08)70236-5
CitationsScopus - 41Web of Science - 36
Co-authorsPeter Greer, Catherine Deste
2007D'Amico AV, Denham J, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al., 'Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions', Journal of Clinical Oncology, 25 2420-2425 (2007) [C1]
DOI10.1200/JCO.2006.09.3369
CitationsWeb of Science - 267
2007D'Amico AV, Denham J, Bolla M, Collette L, Lamb DS, Tai KH, et al., 'Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate', Cancer, 109 2004-2010 (2007) [C1]
DOI10.1002/cncr.22628
CitationsScopus - 22Web of Science - 20
2005Christie D, Denham J, Steigler A, Lamb D, Turner S, Mameghan H, et al., 'Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation', Radiotherapy and oncology, 77 117-125 (2005) [C1]
DOI10.1016/j.radonc.2005.10.005
CitationsScopus - 37Web of Science - 33
Co-authorsCatherine Deste
2005Danham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, et al., 'TROG 96.01: first report of the main endpoints', EJC SUPPLEMENTS, 3 230-231 (2005)
Author URL
2005Denham J, Steigler A, Lamb D, Joseph D, Mameghan H, Turner S, et al., 'Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer : results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial', The Lancet, 6 841-850 (2005) [C1]
DOI10.1016/S1470-2045(05)70348-X
CitationsScopus - 269Web of Science - 235
Co-authorsCatherine Deste
2005Back M, Ahern V, Delaney G, Graham P, Steigler A, Wratten C, 'Absence of adverse early quality of life outcomes of radiation therapy in breast conservation therapy for early breast cancer', Journal of Medical Imaging and Radiation Oncology, 49 39-43 (2005) [C1]
DOI10.1111/j.1440-1673.2005.01392.x
CitationsScopus - 16
2004Back M, Guerrieri M, Wratten C, Steigler A, 'Impact of radiation therapy on acute toxicity in breast conservation therapy for early breast cancer', CLINICAL ONCOLOGY, 16 12-16 (2004)
DOI10.1016/j.clon.2003.08.005Author URL
CitationsScopus - 41Web of Science - 32
2003Denham J, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lam D, et al., 'Relapse patterns after chemo-radiation for carcinoma of the oesophagus', Clinical Oncology, 15 98-108 (2003) [C1]
DOI10.1053/clon.2003.0212
CitationsScopus - 34Web of Science - 30
Co-authorsStephen Ackland
2000Steigler A, Mameghan H, Lamb D, Joseph D, Matthews J, Franklin I, et al., 'A quality assurance audit: Phase 111 trial of maximal androgen deprivation in prostate cancer (TROG 96.01)', AUSTRALASIAN RADIOLOGY, 44 65-71 (2000) [C1]
CitationsScopus - 11
1999Hamilton C, Poulsen M, Walker Q, Krawitz H, Hindley A, Spry N, et al., 'Quality assurance audit in an Australasian phase III trial of accelerated radiotherapy for head and neck cancer (TROG 91.01). Trans-Tasman Radiation Oncology Group.', Australasian radiology, 43 227-232 (1999)
DOI10.1046/j.1440-1673.1999.00639.x
Show 29 more journal articles

Conference (8 outputs)

YearCitationAltmetricsLink
2011Denham J, Steigler A, Lamb DS, Joseph DJ, Matthews J, Atkinson C, et al., 'Variations in androgen dependent clinical progression kinetics in locally advanced prostate cancer', European Journal of Cancer, Stockholm, Sweden (2011) [E3]
Co-authorsCatherine Deste
2007Denham J, Joseph D, Lamb D, Tai KH, Turner S, Matthews J, et al., 'Reasons for initial PSA (iPSA) and biochemical failure (BF) being poor predictors of prostate cancer (PC) mortality', European Journal of Cancer Supplements (ECCO 14 Abstract Book), Barcelona, Spain (2007) [E3]
DOI10.1016/s1359-6349(07)71071-6
Co-authorsPeter Greer
2006Joseph D, Lamb D, Denham J, Tai K-H, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Post treatment variation sand mistaken biochemical failure.', RADIOTHERAPY AND ONCOLOGY, Leipzig, GERMANY (2006)
Author URL
Co-authorsPeter Greer
2006Denham J, Joseph D, Lamb D, Tai K-H, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Doubling time during biochemical failure', RADIOTHERAPY AND ONCOLOGY, Leipzig, GERMANY (2006)
Author URL
Co-authorsPeter Greer
2006Lamb D, Denham J, Joseph D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Post treatment variations and mistaken biochemical failure', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Philadelphia, PA (2006)
DOI10.1016/j.ijrobp.2006.07.632Author URL
Co-authorsPeter Greer
2006Lamb D, Denham J, Joseph D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA: Post treatment variations and mistaken biochemical failure', Proceedings of the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, PA (2006) [E3]
2006Denham J, Joseph D, Lamb D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Doubling time during biochemical failure', Proceedings of the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, PA (2006) [E3]
Co-authorsPeter Greer
2006Joseph D, Denham J, Lamb D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; PSA response signatures (PRS)', Proceedings of the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, PA (2006) [E3]
Show 5 more conferences
Edit

Grants and Funding

Summary

Number of grants1
Total funding$399,565

Click on a grant title below to expand the full details for that specific grant.


20071 grants / $399,565

Optimal duration of neoadjuvant androgen deprivation therapy in localised prostate cancer$399,565

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamConjoint Professor Jim Denham, Mrs Allison Steigler
SchemeProject Grant
RoleInvestigator
Funding Start2007
Funding Finish2007
GNoG0186389
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY
Edit

Mrs Allison Steigler

Position

Statistician
Prostate Cancer Clinical Trials Group
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Emailallison.steigler@newcastle.edu.au
Phone(02) 4985 4019
Fax(02) 4968 4924

Office

RoomWTPO 118
BuildingWaratah Post Office
LocationOther

,
Edit